AbbVie's migraine drug meets main goal in head-to-head study with topiramate
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial.
The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began facing competition from several less expensive biosimilar versions.
The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, to show a lower discontinuation rate due to undesired effect from the treatment than topiramate.
Qulipta was stopped in 12.1% of patients, compared to 29.6% for the generic at 24 weeks.
The European Medicines Agency's safety committee had in 2023 recommended pregnant women not use topiramate-containing medicines to prevent migraine or manage their body weight as their newborns could have a higher risk of neurodevelopmental disorders.
AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches. In comparison, 39.3% patients on topiramate saw a similar reduction.
Qulipta, first approved in the United States in 2021, brought in $658 million in international sales last year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. ('Candid'), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation studies in oncology patients. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases. Share 'We founded Candid on the conviction that T-cell engagers would become the largest therapeutic class in autoimmune diseases, surpassing the commercial success of TNF inhibitors such as Humira,' said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. 'We are hyperfocused on execution to generate clinical data. Over the past few quarters, we have prioritized disease indications and built a foundation of key CMC and clinical operational activities to set a new benchmark for innovation, scale, and speed. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases.' Key Highlights Reinforcing Candid's Leadership Position: First patients dosed with cizutamig and CND261: Patients with refractory rheumatoid arthritis and systemic sclerosis have been dosed at therapeutically active doses. Both TCEs have been well tolerated and patients have shown early signs of promising clinical response and disease improvement. Industry-leading clinical study pipeline in motion: Clinical studies are now in progress for IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Additional clinical studies in high-value disease indications slated to launch in the 2H 2025. Studies are designed to evaluate safety, pharmacokinetics, pharmacodynamic effects, and early signs of efficacy in patients with immunology and inflammatory diseases. CMC activities completed to enable global clinical trials: Candid has invested significant resources to build an integrated Chemistry, Manufacturing, and Controls (CMC) infrastructure to support global development with the completion of several new drug product manufacturing runs. Subcutaneous dosing formulations for both cizutamig and CND261 have been established. Strategic establishment of China operations: To support clinical execution across multiple geographies, Candid has established a fully staffed legal entity in China. The China based team includes professionals with deep expertise in regulatory, clinical development, and clinical operations. With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial initiations and clinical data disclosures are anticipated in the coming quarters. About Candid Therapeutics Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors. About Cizutamig Cizutamig is a bispecific antibody designed to simultaneously bind B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells. Originally developed and clinically evaluated in multiple myeloma, cizutamig has demonstrated patient experience in oncology settings and is now being investigated in autoimmune diseases where pathogenic B-cells play a critical role in disease progression. Cizutamig has the potential to deliver deep and selective B-cell depletion through its dual-targeting mechanism, offering a novel approach for treating a broad spectrum of immune-mediated disorders. About CND261 CND261 is a bispecific antibody designed to target CD20 on B-cells and CD3 on T-cells, enabling T-cell mediated cytotoxicity against CD20-expressing B-cells. Engineered with low CD3 affinity, CND261 is optimized to reduce the risk of excessive T-cell activation while maintaining potent and selective B-cell depletion. The molecule has demonstrated patient experience in B-cell malignancies and is now being investigated in autoimmune diseases where pathogenic B-cells contribute to disease progression. CND261 represents a promising therapeutic candidate for immune-mediated disorders with the potential for improved safety and efficacy through its targeted mechanism of action.
Yahoo
a day ago
- Yahoo
$12.75+ Bn Veterinary Vaccines Market - Global Industry Size, Share, Trends, Opportunities, and Forecasts, 2020-2030F
The key opportunities in the veterinary vaccines market include rising demand for ethical animal products, innovations in vaccine technology, increased animal welfare awareness, and platform-based solutions for new diseases. These factors, along with preventive healthcare trends, are driving global market growth. Veterinary Vaccines Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "Veterinary Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The Veterinary Vaccines Market was valued at USD 8.44 Billion in 2024 and is expected to reach USD 12.76 Billion by 2030, rising at a CAGR of 7.28% This market plays a critical role in veterinary healthcare by providing vaccines designed to prevent and manage diseases in both companion animals and livestock. These vaccines are essential for ensuring animal health, maintaining food security, and reducing the risk of zoonotic disease transmission. Growing demand for ethical and sustainable animal products, coupled with advancements in vaccine technology and the rise of platform-based solutions for emerging diseases, are contributing to market expansion. Innovations like the European Medicines Agency's certification of the Innovax vPTMF, a turkey herpesvirus vector platform, demonstrate the industry's commitment to rapid response and improved vaccine accessibility. As awareness around animal health continues to rise, the veterinary vaccines market is poised for strong growth globally. Key Market Drivers: Growing Awareness of Animal Welfare Increasing public awareness regarding animal welfare is a key factor driving the veterinary vaccines market. Pet owners are more invested in the health of their animals, prioritizing routine vaccinations to extend the life and quality of their pets. Similarly, in livestock farming, the focus on humane treatment and productivity has prompted producers to adopt preventive healthcare strategies, including vaccination. Ethical consumerism is shaping market demand, as buyers prefer products sourced from healthy and well-treated animals. Regulatory frameworks and animal welfare certifications now often include vaccine requirements as part of disease prevention protocols. A notable development is the European Medicines Agency's 2024 certification of the Innovax vPTMF vaccine platform, which enables rapid customization of vaccines to address emerging threats, bolstering preparedness and public health resilience. Key Market Challenges: Regulatory Hurdles and Approval Processes The veterinary vaccines market is significantly impacted by the complex and varying regulatory standards across global regions. Navigating country-specific approval processes presents a substantial challenge for manufacturers, often leading to high compliance costs and extended timelines. Regulatory agencies demand rigorous safety and efficacy evaluations, including detailed preclinical and clinical testing. These requirements, while essential for public and animal health, add layers of complexity that slow down time-to-market for new vaccines. Delays in vaccine registration further hinder growth, especially for companies looking to respond swiftly to evolving disease patterns. Key Market Trends: Increasing Focus on Preventive Healthcare An emerging trend across the veterinary landscape is the heightened emphasis on preventive care through vaccination. Both pet owners and livestock producers are increasingly aware of the benefits of immunization in minimizing disease outbreaks, reducing treatment costs, and enhancing animal welfare. Preventive healthcare is now viewed as a strategic investment, particularly in the companion animal sector where routine vaccinations are standard. In livestock operations, preventive vaccination supports herd health and productivity, reducing economic losses linked to illness. This trend is reshaping the approach to animal care, prioritizing early intervention and long-term health maintenance. Report Scope Key Market Players: Zoetis Inc. Merck & Co. Inc. Virbac SA Hester Biosciences Limited Elanco Animal Health Boehringer Ingelheim International GmbH Ceva Sante Animale Phibro Animal Health Corporation HIPRA Veterinary Vaccines Market, By Vaccine Type: Livestock Vaccine Companion Animal Vaccine Veterinary Vaccines Market, By Technology: Live Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Recombinant Vaccines Other Veterinary Vaccines Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $8.44 Billion Forecasted Market Value (USD) by 2030 $12.76 Billion Compound Annual Growth Rate 7.2% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Veterinary Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
